Aier(SZ:300015)2025-06-23 07:04Group 1: Refractive Technology Development - The company maintains international synchronization and domestic leadership in refractive technology, promoting a variety of personalized and precise medical services [1] - New surgical techniques such as All-Laser LASIK Pro and ICL V5 are expected to meet diverse patient needs, with an average customer price steadily increasing [1] - The acceptance rate for new surgical techniques has been widely validated, while presbyopia surgery remains in its early stages in China, with significant growth potential based on experiences from developed countries [2] Group 2: Vision Care Business Competitiveness - The company's vision care business offers a comprehensive system from prevention to treatment, focusing on a multi-layered approach to myopia control [3] - Core competitiveness is derived from its medical attributes, supported by an improved medical education and research platform, strategic choices, and strong execution [3] - Expansion plans include establishing hospitals in major cities and community clinics equipped with ophthalmologists to enhance patient access and care [3] Group 3: Shareholder Returns - The company emphasizes value creation for society and sharing value with investors through measures like executive stock purchases, share buybacks, and increased dividends [4] - Future projections indicate a continuous increase in dividend amounts and payout ratios as the company transitions into a new development phase with stable operational growth [5] Group 4: Goodwill Management - Goodwill arising from acquisitions is considered a normal financial phenomenon, with strict due diligence and post-acquisition support ensuring project alignment with strategic goals [6] - Annual impairment tests are conducted on goodwill assets, with proactive measures taken to enhance hospital competitiveness and achieve development targets [6]